Current Concepts in Hematopathology

Overview

Essential Topics in Hematopathology CME

In this online CME program, leaders in diagnostic pathology deliver in-depth discussions of microscopic evaluation of hematolymphoid disorders, as well as the appropriate use of a broad range of ancillary studies. Current Concepts in Hematopathology delivers continuing medical education insights, including:

• common pitfalls in the morphologic interpretation and immunophenotyping of hematolymphoid proliferations
• approaches to cases that do not conform to WHO diagnostic categories
• use of evidence-based guidelines, cytogenetics, and molecular testing to inform diagnosis

Topics / Speakers

Nodal Small B-Cell Lymphomas - Elizabeth A. Morgan, MD

Plasma Cell Neoplasms and Lymphoplasmacytic Lymphoma - Valentina Nardi, MD

Question & Answer - Robert P. Hasserjian, MD - Moderator, Elizabeth A. Morgan, MD and Valentina Nardi, MD

Immunodeficiency and Viral-Associated Lymphoproliferations - Judith A. Ferry, MD

Updates in Cutaneous Lymphomas - Sam Sadigh, MD

Question & Answer - Elizabeth A. Morgan, MD - Moderator, Judith A. Ferry, MD and Sam Sadigh, MD

WHO Update - Follicular Lymphoma and Related Entities - Abner Louissaint Jr., MD, PhD

Diffuse Large B-Cell Lymphoma Subtypes - Scott B. Lovitch, MD, PhD

Question & Answer - Marian H. Harris, MD - Moderator, Abner Louissaint Jr, MD, PhD and Scott B. Lovitch, MD, PhD

Burkitt Lymphoma and High-Grade B-Cell Lymphomas – A Practical Guide and Update - Aliyah R. Sohani, MD

Reactive Lymphadenopathies and Castleman Disease - Yasodha Natkunam, MD, PhD

Question & Answer - Robert P. Hasserjian, MD - Moderator, Yasodha Natkunam, MD, PhD and Aliyah R. Sohani, MD

Approach to Peripheral Smear Review - Elizabeth Courville, MD

Myelodysplastic Syndrome and Its Differential Diagnosis - Robert P. Hasserjian, MD

Question & Answer - Elizabeth A. Morgan, MD - Moderator, Elizabeth Courville, MD and Robert P. Hasserjian, MD

Acute Myeloid Leukemia and Acute Leukemias of Ambiguous Lineage - Olga K. Weinberg, MD

Acute Lymphoblastic Leukemia - Marian H. Harris, MD, PhD

Question & Answer - Robert P. Hasserjian, MD - Moderator, Marian H. Harris, MD, PhD and Olga K. Weinberg, MD

Eosinophilia and Mastocytosis - Olga Pozdnyakova, MD, PhD

Myelodysplastic/Myeloproliferative Neoplasms - Robert P. Hasserjian, MD

Question & Answer - Marian H. Harris, MD, PhD - Moderator, Robert P. Hasserjian, MD and Olga Pozdnyakova, MD, PhD

Interpreting Flow Cytometry Minimal Residual Disease in Acute Leukemia - Sa A. Wang, MD

Practical Interpretation of Molecular Testing in Myeloid Neoplasms - Annette S. Kim, MD, PhD

Question & Answer - Elizabeth A. Morgan, MD - Moderator, Annette S. Kim, MD, PhD and Sa A. Wang, MD

Challenges in the Diagnosis of Hodgkin Lymphomas - Marian H. Harris, MD, PhD

Primary Mediastinal Large B-Cell and Grey-Zone Lymphomas - Scott J. Rodig, MD, PhD

Question & Answer - Robert P. Hasserjian, MD - Moderator, Marian H. Harris, MD, PhD and Scott J. Rodig, MD, PhD

Indolent T-Cell Disorders - Kathleen H. Burns, MD, PhD

Nodal T-Cell Lymphomas - Roberto Chiarle, MD

Question & Answer - Marian H. Harris, MD, PhD - Moderator, Kathleen H. Burns, MD, PhD and Roberto Chiarle, MD

Histiocytic and Dendritic Cell Neoplasms - Elizabeth A. Morgan, MD

IgG4-Related Disease and Lymphadenopathy - Jacob R. Bledsoe, MD

Blastic Plasmacytoid Dendritic Cell Neoplasm - Gabriel K. Griffin, MD

Question & Answer - Marian H. Harris, MD, PhD - Moderator, Jacob R. Bledsoe, MD, Gabriel K. Griffin, MD and Elizabeth A. Morgan, MD

Inherited Predisposition to Myeloid (and Hematological) Malignancies - Mark D. Fleming, MD, DPhil

Spleen Pathology - Lawrence R. Zukerberg, MD

Question & Answer - Elizabeth A. Morgan, MD - Moderator, Mark D. Fleming, MD, DPhil and Lawrence R. Zukerberg, MD

Faculty

Accreditation

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The Harvard Medical School designates this enduring material for a maximum of 20.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Pathology (ABP)

This activity is approved for 20.25 Lifelong Learning (Part II) credits towards the American Board of Pathology’s Maintenance of Certification Program.

Date of Original Release: June 30, 2022

Termination Date: June 30, 2025 (Please note that AMA PRA Category 1 Credits™ will no longer be issued for the activity after this date)
Estimated Time to Complete the Activity: 20.25 hours

CME credit is awarded upon successful completion of a course evaluation and post-test.

ACGME Competencies

This course is designed to meet one or more of the following Accreditation Council for Graduate Medical Education Competencies:

• Interpersonal and Communication Skills

Learning Objectives

Upon completion of this activity, participants will be able to:

• Correctly use morphologic criteria and cost-effectively use ancillary studies to diagnose a broad range of lymph node and bone marrow pathologies
• Apply evidence-based criteria to the diagnosis of myeloid and lymphoid neoplasms
• Diagnose challenging cases that do not readily conform to well-established entities
• Evaluate and distinguish hematolymphoid malignancies from non-neoplastic mimics of malignancy

Target Audience

This course is targeted to specialty physicians who practice in pathology.

Disclosure Policy

Harvard Medical School (HMS) adheres to all ACCME Accreditation Criteria and Policies. It is HMS's policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

Disclosure information for all individuals in control of the content of the activity is located on the disclosure statement in the PDF and printed syllabus.